Literature DB >> 24562705

[Risk-adapted surveillance: focus on familial breast and ovarian cancer].

K Rhiem1, R K Schmutzler.   

Abstract

Breast cancer surveillance programs for the general population are not adequate for the small number of women with hereditary breast and ovarian cancer syndrome. Breast cancer screening for women in Germany starts at the age of 50 years, but nearly half of all women with familial risk are already diagnosed with breast cancer at that time. Moreover, mammography alone is not suitable for an early diagnosis of breast cancer in young women from high-risk families. Their typical dense breast tissue causes a high rate of false-negative cases. Therefore, national and international prospective clinical trials were initiated to offer a multimodal breast cancer surveillance program including magnetic resonance tomography for the breast and semi-annual screening intervals to women with BRCA1/2 mutations and those from high-risk families who tested negative for BRCA1/2 mutations. This program will currently be evaluated by the 15 centers of the German Consortium for Hereditary Breast and Ovarian Cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24562705     DOI: 10.1007/s00103-013-1910-3

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  3 in total

1.  Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.

Authors:  Sarah M Nielsen; Diana M Eccles; Iris L Romero; Fahd Al-Mulla; Judith Balmaña; Michela Biancolella; Rien Bslok; Maria Adelaide Caligo; Mariarosaria Calvello; Gabriele Lorenzo Capone; Pietro Cavalli; T L Chris Chan; Kathleen B M Claes; Laura Cortesi; Fergus J Couch; Miguel de la Hoya; Simona De Toffol; Orland Diez; Susan M Domchek; Ros Eeles; Anna Efremidis; Florentia Fostira; David Goldgar; Andreas Hadjisavvas; Thomas V O Hansen; Akira Hirasawa; Claude Houdayer; Petra Kleiblova; Sophie Krieger; Conxi Lázaro; Maria Loizidou; Siranoush Manoukian; Arjen R Mensenkamp; Setareh Moghadasi; Alvaro N Monteiro; Luigi Mori; April Morrow; Nadia Naldi; Henriette R Nielsen; Olufunmilayo I Olopade; Nicholas S Pachter; Edenir I Palmero; Inge S Pedersen; Maria Piane; Marianna Puzzo; Mark Robson; Maria Rossing; Maria Christina Sini; Angela Solano; Jana Soukupova; Gianluca Tedaldi; Manuel Teixeira; Mads Thomassen; Maria Grazia Tibiletti; Amanda Toland; Therese Törngren; Erica Vaccari; Liliana Varesco; Ana Vega; Yvonne Wallis; Barbara Wappenschmidt; Jeffrey Weitzel; Amanda B Spurdle; Arcangela De Nicolo; Encarna B Gómez-García
Journal:  JCO Precis Oncol       Date:  2018-10-26

2.  Digital breast tomosynthesis plus synthesised images versus standard full-field digital mammography in population-based screening (TOSYMA): protocol of a randomised controlled trial.

Authors:  Stefanie Weigel; Joachim Gerss; Hans-Werner Hense; Miriam Krischke; Alexander Sommer; Jörg Czwoydzinski; Horst Lenzen; Laura Kerschke; Karin Spieker; Stefanie Dickmaenken; Sonja Baier; Marc Urban; Gerold Hecht; Oliver Heidinger; Joachim Kieschke; Walter Heindel
Journal:  BMJ Open       Date:  2018-05-14       Impact factor: 2.692

3.  Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.

Authors:  A Isselhard; M Töpper; B Berger-Höger; A Steckelberg; H Fischer; F Vitinius; K Beifus; J Köberlein-Neu; R Wiedemann; K Rhiem; R Schmutzler; S Stock
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.